<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114484">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132767</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 08-1078-00007</org_study_id>
    <secondary_id>5U01HL088942-08</secondary_id>
    <nct_id>NCT02132767</nct_id>
  </id_info>
  <brief_title>Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation</brief_title>
  <official_title>Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Canadian Institutes of Health Research  (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mount Sinai School of Medicine</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>Canada: Canadian Institutes of Health Research</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the therapeutic strategies of rate control versus
      rhythm control in cardiac surgery patients who develop in-hospital postoperative atrial
      fibrillation or atrial flutter (AF).  In patients who develop AF during hospitalization
      after cardiac surgery, the hypothesis is that a strategy of rhythm control will reduce days
      in hospital within 60 days of the occurrence of AF compared to a strategy of rate control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the research is to compare two strategies for treating atrial fibrillation or
      atrial flutter, both of which are referred to as AF, after cardiac surgery.  AF is the most
      common complication after cardiac surgery.  AF is when the upper chambers of the heart
      (atria) experience disorganized electrical activity which causes the heart beat to be
      irregular.  The two treatment strategies to be used in this study are called rhythm control
      and rate control.  The rhythm control strategy will attempt to bring the heart beat back to
      a regular rhythm using treatments known and approved to control heart rhythm.  The rate
      control strategy will attempt to bring the heart rate to less than 100 beats per minute at
      rest using medications known and recommended to control heart rate.  Both strategies are
      commonly used to treat AF.  All of the medications that will be used in this study are the
      standard of care for use in patients experiencing AF.  This research seeks to determine
      whether rhythm control is better than rate control in patients with AF after cardiac
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Total number of days in hospital</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>The total number of days in hospital for any hospitalization that occurs within 60 days of randomization to AF treatment strategy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AF- or treatment-related events</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to conversion to sustained, stable non-AF rhythm</measure>
    <time_frame>Up to 60 days post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rhythm comparison</measure>
    <time_frame>Hospital discharge and 30 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare heart rhythm at hospital discharge and at 30 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rhythm comparison</measure>
    <time_frame>Hospital discharge and 60 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare heart rhythm at hospital discharge and at 60 days after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (index hospitalization)</measure>
    <time_frame>Within 60 days post surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall length of stay for the index hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Stay (rehospitalization, including ED visits)</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare frequency of readmissions between groups for any cause and AF-related hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outpatient Interventions</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare frequency of outpatient visits between groups for any cause and AF-related causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost (hospital)</measure>
    <time_frame>Within 60 days of randomization</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare cost of index hospitalization and cost of rehospitalizations (including ED visits) between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">470</enrollment>
  <condition>Postoperative Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Rhythm control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rhythm Control in post-operative AF
Amiodarone and/or DC-cardioversion
Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started
DC-Cardioversion - frequency and duration determined by medical professional as medically needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rate control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rate Control in post-operative AF
Beta-blocker and/or Calcium channel blockers and/or Digoxin
Dose, frequency and duration determined by medical professional as medically needed</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amiodarone</intervention_name>
    <description>Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started</description>
    <arm_group_label>Rhythm control</arm_group_label>
    <other_name>Cordarone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>DC-cardioversion</intervention_name>
    <description>DC-Cardioversion - frequency and duration determined by medical professional as medically needed</description>
    <arm_group_label>Rhythm control</arm_group_label>
    <other_name>Direct Current Cardioversion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rate Control</intervention_name>
    <description>Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed</description>
    <arm_group_label>Rate control</arm_group_label>
    <other_name>Beta-blocker</other_name>
    <other_name>Calcium channel blockers</other_name>
    <other_name>Digoxin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Enrollment Inclusion Criteria:

          -  Age  &gt; 18 years

          -  Undergoing heart surgery for coronary artery bypass (on-pump or off-pump CABG) and/or
             valve repair or replacement (excluding mechanical valves), including re-operations

          -  Hemodynamically stable

        Randomization Inclusion Criteria

          -  AF that persists for &gt; 60 minutes or recurrent (more than one) episodes of AF up to 7
             days after surgery during the index hospitalization.

        Exclusion Criteria:

          -  LVAD insertion or heart transplantation

          -  Maze procedure

          -  TAVR

          -  History of or planned mechanical valve replacement

          -  Correction of complex congenital cardiac defect (excluding bicuspid aortic valve,
             atrial septal defect or PFO)

          -  History of AF or AFL

          -  History of AF or AFL ablation

          -  Contraindications to warfarin or amiodarone

          -  Need for long-term anticoagulation

          -  Concurrent participation in an interventional (drug or device) trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy J Gardner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiothoracic Surgical Trials Network</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick T O'Gara, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiothoracic Surgical Trials Network</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kinjal Shah, PA-C</last_name>
    <phone>212-659-8399</phone>
    <email>kinjal.shah@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annetine C Gelijns, PhD</last_name>
    <phone>212-659-9567</phone>
    <email>annetine.gelijns@mssm.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shadi Van Trease, BA, CCRC</last_name>
      <email>Shadi.VanTrease@med.usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Edward Lozano</last_name>
      <email>edwardlo@med.usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Bowdish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tamara Prince, RN, MSN</last_name>
      <phone>404-686-3374</phone>
      <email>t.prince@emoryhealthcare.org</email>
    </contact>
    <contact_backup>
      <last_name>Kim Baio, RN, MSN</last_name>
      <phone>404-686-3374</phone>
      <email>kim.baio@emoryhealthcare.org</email>
    </contact_backup>
    <investigator>
      <last_name>Vinod Thourani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Whinnery</last_name>
      <email>jwhinnery@smail.umaryland.edu</email>
    </contact>
    <contact_backup>
      <last_name>Dorothy Bryant</last_name>
      <email>DBryant@smail.umaryland.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James S Gammie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NIH Heart Center at Suburban Hospital</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandy Murphy, RN, CCRC</last_name>
      <phone>301-896-3775</phone>
      <email>MMurphy@SuburbanHospital.org</email>
    </contact>
    <contact_backup>
      <last_name>Ann Greenberg, RN, MSN</last_name>
      <phone>301-896-2473</phone>
      <email>agreenberg@suburbanhospital.org</email>
    </contact_backup>
    <investigator>
      <last_name>Keith Horvath, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Services</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathie Bloem, MPH, RN</last_name>
      <email>bloem@umich.edu</email>
    </contact>
    <investigator>
      <last_name>Steven Bolling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Einstein Heart Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roger Swayze, RN, BSN, MBA</last_name>
      <phone>718-920-2221</phone>
      <email>rswayze@montefiore.org</email>
    </contact>
    <contact_backup>
      <last_name>Nadia Sookraj</last_name>
      <phone>718-920-6636</phone>
      <email>NSOOKRAJ@montefiore.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert Michler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lyn Goldsmith, MA, RN, BSN, CCRC</last_name>
      <phone>212-342-0261</phone>
      <email>Lg2240@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Argenziano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ilja Dejanovic</last_name>
      <email>ilja.dejanovic@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>David H Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tracy Nanney</last_name>
      <email>Tracy.Nanney@msj.org</email>
    </contact>
    <contact_backup>
      <last_name>Ralph Mangusan</last_name>
      <email>Ralph.Mangusan@msj.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mark A Groh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stacey Welsh, RN</last_name>
      <phone>919-684-2037</phone>
      <email>Welsh010@mc.duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Victoria Sutton</last_name>
      <phone>919-613-5621</phone>
      <email>victoria.sutton@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carrie Geither</last_name>
      <phone>216-445-4748</phone>
      <email>GEITHEC@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Kristin Doud</last_name>
      <phone>216-445-4437</phone>
      <email>DOUDK@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Bruce Lytle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asia McDavid, MS</last_name>
      <phone>614-688-7904</phone>
      <email>Asia.McDavid@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Christie Hartlev</last_name>
      <email>christie.hartlev@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Chittoor Sai-Sudhakar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Lou Mayer, BSN, CCRN, CCRC</last_name>
      <phone>215-662-7981</phone>
      <email>Marylou.mayer@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katie Tremont, BS</last_name>
      <phone>215-615-0518</phone>
      <email>Katie.tremont@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael A Acker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cynthia Boudreaux, M.Ed.</last_name>
      <email>clb@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Faisal G Bakaeen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracine Adame, RN, CRC</last_name>
      <phone>469-814-4735</phone>
      <email>Tracine.adame@baylorhealth.edu</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Settele, PA-C</last_name>
      <email>Natalie.Settele@baylorhealth.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Mack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandra G Burks, RN, CCRC</last_name>
      <phone>434-243-0315</phone>
      <email>sgb2c@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kimberly Gahring, RN</last_name>
      <phone>434-243-3178</phone>
      <email>Kag3x@hscmail.mcc.virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Irving L Kron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lauren Godbole</last_name>
      <email>GODBOLE@surgery.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Shahab A Akhter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emily Kuurstra</last_name>
      <email>Emily.Kuurstra@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>John C Mullen, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Garrand</last_name>
      <email>lisa.garrard@uhn.ca</email>
    </contact>
    <investigator>
      <last_name>Terry Yau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joannie Dionne</last_name>
      <email>joannie.dionne.chum@ssss.gouv.qc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Julie Fecteau</last_name>
      <email>julie.fecteau.chum@ssss.gouv.qc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas Noiseux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital du Sacré-Cœur de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole Sirois</last_name>
      <email>carole.sirois@crhsc.rtss.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Huges Jeanmart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Robichaud, RT</last_name>
      <phone>514-376-3330</phone>
      <email>Sophie.Robichaud@icm-mhi.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonathan Lacharité</last_name>
      <phone>514-376-3330</phone>
      <email>jonathan.lacharite@icm-mhi.org</email>
    </contact_backup>
    <investigator>
      <last_name>Hugues Jeanmart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie de Quebec (Hopital Laval)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gladys Dussault</last_name>
      <phone>418-656-8711</phone>
      <email>Gladys.dussault@criucpq.ulaval.ca</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Keilani</last_name>
      <email>Suzanne.keilani@criucpq.ulaval.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre Voisine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.ctsurgerynet.org/</url>
    <description>Cardiothoracic Surgical Trials Network Website</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 5, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mount Sinai School of Medicine</investigator_affiliation>
    <investigator_full_name>Annetine Gelijns</investigator_full_name>
    <investigator_title>Professor and Chair, Health Evidence and Policy</investigator_title>
  </responsible_party>
  <keyword>Heart surgery</keyword>
  <keyword>Cardiac surgery</keyword>
  <keyword>Coronary artery bypass</keyword>
  <keyword>Mitral valve surgery</keyword>
  <keyword>Aortic valve surgery</keyword>
  <keyword>Atrial fibrillation</keyword>
  <keyword>Atrial flutter</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <keyword>Valve surgery</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
